EMA Recommends Compassionate Use of Remdesivir for COVID-19
EMA's CHMP has recommended the use of remdesivir, an investigational antiviral medicine, in compassionate use programs across the European Union.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of remdesivir, an investigational antiviral medicine, in compassionate use programs across the European Union.
As reported in an April 3, 2020 press release, CHMP’s recommendation was given in a virtual meeting held on April 2, 2020, and means that patients with COVID-19 can be administered remdesivir through compassionate use. The recommendation describes which patients may benefit from the early use of the medicine, how to use the medicine, and preliminary information on the safety of the medicine.
“Clinical trials remain the gold standard for the collection of robust data on the safety and effectiveness of investigational medicinal products, but CHMP acknowledges the need for a harmonized approach to compassionate use in the EU to allow access to remdesivir for patients who are not eligible for inclusion in clinical trials,” said Dr. Harald Enzmann, the chair of the CHMP, in the press release. “CHMP encourages the company to make remdesivir available in a fair and transparent way to those member states wishing to take part in international clinical trials or treat patients in compassionate use programs.”
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
